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Abstract
Background: We previously showed that blood serum induced cytochrome P450 1A1 (CYP1A1) monooxygenase expression
in vitro.
Objective: Our purpose was (i) to identify the molecular mechanism involved and (ii) to characterize the inducer
compound(s) in serum involved at least in part.
Methods: Serum was fractionated on hydrophobic columns. PPARa involvement was demonstrated by gene reporter
assays, DNA mutagenesis and EMSA. Gene expression was evaluated by qRT-PCR. Serum samples were analyzed using HS-
SPME-GC-MS.
Results: The inductive effect of serum did not depend on the AhR pathway and was enhanced by cotransfection of PPARa
cDNA. Mutations in the PPAR response elements of the CYP1A1 gene promoter suppressed this effect. One of the PPRE sites
appeared highly specific for human PPARa, an unreported PPRE property. A link was found between CYP1A1 inducibility
and serum hydrophobic compounds. Characterization of sera showed that hexanal, a metabolite produced by peroxidation
of linoleic acid, was involved in CYP1A1 induction by serum, possibly along with other serum entities.
Conclusion: We demonstrate that serum induces CYP1A1 via the PPARa pathway and that hexanal is one of the serum
inducers. The two PPRE sites within the CYP1A1 promoter are functional and one of them is specific for PPARa.
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Introduction
Cytochromes P450 (CYP) are monooxygenases involved in the
metabolism and degradation of xenobiotics, including procarcinogens
such as arylamines and polycyclic aromatic hydrocarbons (PAHs) [1].
Among the CYP, CYP1A1 plays a physiological role in the
degradation of estradiol into 2-OH-estradiol [2]. These metabolisms
elicit the production of reactive oxygen species (ROS). CYP1A1 gene
expression is mainly regulated by the aryl hydrocarbon receptor (AhR)
activated by xenobiotics including dioxins and polycyclic aromatic
hydrocarbons [3]. Endogenous agonist AhR ligands (such as bilirubin,
tryptophan-N-formylated derivatives and lipoxin A4) have already
been identified, together with an endogenous antagonist, 7-ketocho-
lesterol [4], [5], [6], [7]. However, the role of endogenous AhR ligands
in cell physiology remains poorly understood. The activated
AhR migrates into the nucleus, interacts with its partner, the aryl
hydrocarbon receptor nuclear translocator (ARNT) and the heterodi-
mer binds DNA at specific dioxin-responsive elements (DRE) [8].
There is little data available on CYP1A1 expression stimulation
by other regulatory pathways. Retinoic acid (RA) exerts a weak
transactivation through a RARE (retinoid acid responsive element)
sequence in the CYP1A1 promoter [9], but essentially inhibits
AhR activity through SMRT displacement [10], [11]. We
previously identified PPARa as a mediator of CYP1A1 induction
[12]. Free fatty acids (FA) may act as PPAR ligands. Polyunsat-
urated FA (PUFA) are PPARc and PPAPa agonists [13], [14], but
less is known about saturated, peroxidized, halogenated or thio-
derivatives of FA. We hypothesized that serum containing a high
level of FA could induce CYP1A1 expression through PPARa
activation by one or more discrete FA species or derivatives.
Several clinical reports have shown that local CYP1A1
overexpression correlates with predisposition to various human
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14629cancers, including colon and non-small cell lung cancers (NSCLC)
[15].
We report here that serum-mediated CYP1A1 induction involves
PPARa and two PPRE sites within the CYP1A1 promoter
(positions –931/-919 and –531/-519, named PPRE1 and PPRE2),
and that the proximal PPRE site is a new human PPARa-specific
consensussite.Inparallel,wehavecharacterizedone serumproduct
derived from the peroxidation of linoleic acid, hexanal, that is at
least partly responsible for intestinal CYP1A1 induction.
Materials and Methods
Culture and cell treatments
Human colic adenocarcinoma cells CaCo-2 and HT29-D4,
human hepatoma cells Hep G2, human pulmonary cells A549 and
primary human keratinocytes (obtained under ethical conditions),
were cultured as previously described [16]. After 80% confluence,
cells were starved for 24 h without FBS (replaced by 0.2% BSA)
and treated for 6 h with 20% FBS or a low-FA FBS (FBSLess); or
1 mM of 3-methyl-cholanthrene (3-MC); or 100 mM of WY-
14643; or 1 mM of retinoic acid (RA); or 200 mM of free FA
(palmitic, stearic, linoleic, a-linolenic, c-linolenic, arachidonic or
eicosapentaenoic acid); or 5, 10, 25, 50, 100 and 200 mMo f
hexanal (Sigma, France). Control cells were treated with the
solvent used to dissolve the compounds (DMSO).
Quantitative RT-PCR experiments
Total RNA was isolated using a Nucleospin RNAII kit
(Macherey-Nagel, France) and reverse-transcribed at 37uC for
1 h using GibcoBRL M-MLV reverse-transcriptase (Life Tech-
nologies, France) and random primers. CYP1A1 mRNA expres-
sion, normalized to b2-microglobulin, was determined using the
LightCycler System (Roche Diagnostics, France). The CYP1A1





PCR was performed as previously described [17]. The results
are expressed as relative expression levels (REL). At least three
independent experiments were carried out in triplicate.
CAT assays
Cells were placed in six-well plates and transfected using lipofectin
(Life Technologies, France) with 1 mg of a chimeric construction
including the 21140/+80 region of CYP1A1 gene, (pRNH25c), or
1 mg of DRE-TK-CAT construct [16] driving chloramphenicol
acetyltransferase (CAT). In some experiments, 1 mgo fp s G 5
PPARacDNA [18] was cotransfected. After an 18 h incubation
p e r i o d ,c e l l sw e r et r e a t e d2 4hl a t e rw i t h2 0 %F B So r1mM3 - M Co r
100 mM WY-14643 and harvested after a further 24 h. CAT
expression was then evaluated by quantifying CAT protein using the
CAT Elisa System (Roche Diagnostics, France) [19]. The transfection
efficiency was normalized using beta-Galactosidase expression vector.
At least three independent experiments were carried out in triplicate.
LUCIFERASE assays
Cells were placed in six-well plates and transfected using
lipofectin with 1 mg of a chimeric construction including three
PPRE sequences driving luciferase (LUC) gene expression (PPRE-
TK-LUC), and treated as described above. LUC enzymatic
activity was then evaluated. The transfection efficiency was
normalized using beta-Galactosidase expression vector. At least
three independent experiments were carried out in triplicate.
Site-directed mutagenesis of CYP1A1 promoter
PPRE mutations of pRNH25c were introduced using the
QuickChange site-directed mutagenesis kit (Stratagene, France) to
obtain pRNH25c-DPPRE as previously described [12]. Cells were
transfected by the pRNH25c or the pRNH25c- DPPRE and after
a 48 h treatment with 100 mM WY-14643, 20% FBS or 1 mM3 -
MC the CAT expression was evaluated as described above. The
transfection efficiency was normalized using beta-Galactosidase
expression vector.
FBS treatment by XAD2 column or active charcoal
50 ml of FBS was run through either an XAD2 column (Sigma,
France) or active charcoal. The retained hydrophobic elements
were eluted from the XAD2 column with methanol, and from
active charcoal with methanol, ethyl acetate or hexane. After
solvent evaporation the eluted compounds were resuspended in
50 ml of FBS free culture medium.
In vitro translation and electromobility shift assays
(EMSA)
EMSA were performed using PPARa and RXRa prepared by in
vitro translation (Promega, France). Proteins were incubated for 20
minutesatroomtemperaturewith50.000cpmofT4polynucleotide
kinase-labeled oligonucleotides (in 10 mM Tris pH 8.0, 100 mM
KCl, 10% glycerol, 1 mM dithiothreitol, 1 mg of poly-dIdC and
0.5 mg of salmon sperm) and separated on a 4% polyacrylamide gel.
The oligonucleotides used as either radiolabeled probes or
competitors (sense strands are shown, with core sequence
underlined and mutation in bold-face) as previously described [12].
Autoradiography was carried out on Kodak X-AR film.
Determination of lipid serum composition
Total lipids were extracted from 1 ml aliquots of FBS and
FBSLess using the Folch method modified by Hernell [20], [21].
The chloroform fraction containing lipids was evaporated to
dryness under nitrogen, and the lipid pellet was suspended in
isopropanol. Triglycerides, total cholesterol and free fatty acids
were assayed by colorimetry using specific commercial kits
(Triglyceride/Free glycerol reagent from Sigma, Cholesterol
CHOD-PAP from Roche Diagnostic, NEFA from Randox,
respectively), and phospholipids were assayed by phosphorus
determination [22]. Fatty acid profiles were determined after
methylation with BF3-methanol (Sigma, St Louis, MO) by gas
chromatography [23] using a Perkin Elmer Autosystem XL
(Perkin Elmer, Courtaboeuf, France) equipped with a fused silica
capillary column (Omegawax 250, 30 m 60.25 mm i.d., film
thickness 0.25 mm; Sigma-Supelco), equipped with a flame
ionization detector and the Turbochrom software. Hydrogen
was used as carrier gas. The oven temperature was ramped from
60uC to 215uCa t4 5 uC/min. Fatty acids were identified by their
retention times against standards (PUFA 2, Sigma-Supelco).
HS-SPME-GC-MS analysis of volatile compounds in FBS
and FBSLess sera
Substances derived from FA peroxidation were sought in both
sera. Headspace solid-phase microextraction (HS-SPME) was used
to extract the volatile organic compounds, which then underwent
qualitative analysis by gas chromatography–mass spectrometry
(GC-MS). HS-SPME was performed with an AOC-5000 auto-
sampler: 1 ml of serum was placed in a sealed 20 ml vial and
thermostated at 37uC for 15 min before introduction of the fiber
(carboxenTM- PDMS, length 10 mm, thickness 75 mm, Supelco Inc.,
Bellefonte, USA). The fiber was exposed to the vapor phase for 5 min
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port of the GC-MS (GC QP 20120, Shimadzu) using an inlet liner
(0.75 mm i.d.) set at 250uC for thermal desorption for 3 min. (splitless
mode, purge opened after 0.5 min.). Volatiles were separated on an
UBWAX column (30 m 60.25 mm, 0.5 mm, Interchim, Montluc ¸on,
France). The carrier gas was He at a velocity of 35 cm.s
21.T h eo v e n
program temperature was as follows: 40uCf o r1m i n ,3 uCm i n
21 to
100uCa n d5 uCm i n
21to 220uC. The mass spectrometer was operated
i nt h ee l e c t r o ni m p a c tm o d ea t7 0e Vi nt h em/z range 29–300 at a
speed of 2 scans s
21. The temperatures of the ion source and transfer
line were 200uCa n d2 4 0 uC. Detected compounds were identified by
matching spectra against the NIST library (v.2.0).
Statistical Analysis
Results are expressed as means 6 SD. Data were analyzed
using Wicoxon signed rank test. P values less than 0.05 were
considered significant. All analyses were done using the STAT-
VIEW software (Abacus Concepts, Berkeley, CA, USA).
Results
FBS induced CYP1A1 in different cell lines independently
of AhR
We studied the inducibility of CYP1A1 mRNA by serum in A549
CaCo-2, HepG2, HT29-D4 cells and human primary keratinocytes.
As shown in Figure 1A, 3-MC induced CYP1A1 mRNA in all the cell
lines tested, while serum induced CYP1A1 expression in all the cell
lines except the human HT29-D4 adenocarcinoma cell line. As CaCo-
2 cells are high-responsive, we chose this cell line to study the molecular
mechanism involved in the CYP1A1 induction process by serum. We
also performed reporter gene assays where CAT expression was driven
by two DRE sequences. As shown in Figure 1B, in CaCo-2 cells, this
construct was inducible by 3-MC but not by serum. In addition we
studied, in HT29-D4 and CaCo-2 cells, the AhR protein nuclear
translocation after 3-MC or FBS treatments. Result (data not shown)
s h o w nt h a t3 - M C ,b u tn o ts e r u m ,i sa b l et oi n d u c eA h Rn u c l e a r
translocation in the two studied cell lines.
CYP1A1 inducers present in serum are hydrophobic
We fractionated FBS by chromatography through XAD2 or
active charcoal columns to study the chemical nature of the
CYP1A1 inducers. Retained hydrophobic compounds were eluted
from the XAD2 column by methanol and from the active charcoal
by methanol, ethyl acetate, or hexane. As shown in Figure 2A and
2B, CYP1A1 inducers contained in serum were retained by both
XAD2 and charcoal, since there was no induction with the flow-
through fraction (Figure 2A, lane 2 and Figure 2B, lane 2). The
inducers were eluted from both XAD2 (with methanol) (Figure 2A,
lane 3) and charcoal (with ethyl acetate, hexane, or methanol), as
the eluate elicited CYP1A1 induction (Figure 2B, lanes 3, 4, 5).
Figure 2. Effect of FBS fractions on CYP1A1 mRNA levels. 2A: Results obtained after XAD2-bound or unbound fractions of FBS. C: control cells;
1: cells treated with FBS; 2: cells treated with XAD2-unbound fraction; 3: cells treated with XAD2-bound fraction eluted with methanol. 2B: Results
obtained after charcoal-bound or unbound fractions of FBS. C: control cells; 1: cells treated with FBS. Cells were treated with either unbound-charcoal
fraction (lane 2) or compounds eluted from charcoal by methanol (lane 3), ethyl acetate (lane 4) or hexane (lane 5).
doi:10.1371/journal.pone.0014629.g002
Figure 1. CYP1A1 induction by FBS is independent of AhR. 1A: CYP1A1 mRNA levels in various cell lines after a 6 h treatment by 20% FBS or
1 mM 3-MC. 1B: CaCo-2 cells were transfected with the DRE-TK-CAT construct and treated with 20% FBS, 1 mM 3-MC or 100 mM WY-14643. CAT
expression was evaluated 24 h later.
doi:10.1371/journal.pone.0014629.g001
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hydrophobic compound (Figure 2) rather than proteins, as
MgSO4 protein precipitation had no effect on CYP1A1 induction
by FBS (data not shown).
CYP1A1 induction by FBS involves PPARa
In addition to the AhR-dependent DRE sites, CYP1A1 can also
be induced through two PPRE sites and one RARE. We treated
CaCo-2 cells for 6 h with FBS, WY-14643 (a PPARa ligand),
TZD (a PPARc ligand), RA or 3-MC. As shown in Figure 3A,
TZD did not increase CYP1A1 mRNA levels, whereas there was a
marked induction with the WY-14643, FBS and 3-MC treatments
and a weaker induction with RA.
To confirm that FBS was able to induce CYP1A1 through
PPRE sequences, we transfected CaCo-2 cells with either
pRNH25c, or pRNH25c- DPPRE. Cells were treated with FBS
or WY-14643 for 48 h. As shown in Figure 3B, FBS and WY-
14643 efficiently induced CYP1A1 promoter transactivation (2.5-
fold) while the mutation of one PPRE site alone slightly reduced
luciferase activity, and the mutations of the two PPRE sites
abrogated it. We observed that CYP1A1 promotor activation by
3-MC is independent of PPRE sites, this activation being lower
when PPRE sites were mutated.
FBS-mediated CYP1A1 induction was increased by cotransfec-
tion of a PPARa expression vector (2-fold) (Figure 3C). Finally, as
shown in Figure 3D, both FBS and WY-14643 were able to
transactivate reporter constructs driven by a canonical PPRE
sequence, while no induction was observed with 3-MC. In
addition, WY-14643 was unable to transactivate DRE sequences
(Figure 1B).
We investigated the PPARa-binding ability of each CYP1A1
PPRE. Given that TZD did not induce CYP1A1 expression and
Figure 3. Effect of PPRE on CYP1A1 promoter activation. CaCo-2 cells were either left untreated (C) or treated for 6 h with either: 20% FBS,
100 mM WY-14643, 200 mM 2, 4-thiazolidinedione, 1 mM RA, or 1 mM 3-MC (3A). Before treatments CaCo2 cells were transfected with wild-type
pRNH25c or pRNH25c-DPPRE1, pRNH25c- DPPRE2 or pRNH25c- DPPREs (3B) and treated with serum or 100 mM WY-14643 or 1 mM 3-MC. CAT
expression was evaluated. Statistical analyses were performed by comparing mutated PPRE constructions to the wild-type construct. 3C: Effect of
PPARa cDNA transfection on CYP1A1 mRNA induction by FBS. 3D: CaCo-2 cells were transfected by PPRE-TK-LUC and treated with 1 mM 3-MC, 20%
FBS, 100 mM WY-14643 or 25 mM hexanal (HEX). C: cells treated with solvent.
doi:10.1371/journal.pone.0014629.g003
Figure 4. Detection of PPARa binding on the two CYP1A1 PPRE
sites by Gel shift assay. A PPRE canonical sequence, the CYP1A1
PPRE1 (position –931/-919) and the CYP1A1 PPRE2 (position –519/-531)
were tested. 1: TNT + PPRE canonical sequence; 2: TNT + RXR + PPRE
canonical sequence; 3: TNT + RXR + PPARa + PPRE canonical sequence;
4: TNT + RXR + PPARc + PPRE canonical sequence; 5: TNT + PPRE 1;
6: TNT + RXR + PPRE 1; 7: TNT + RXR + PPARa + PPRE 1; 8: TNT + RXR +
PPARc + PPRE 1; 9: TNT + PPRE2; 10: TNT + RXR + PPRE2; 11: TNT + RXR
+ PPARa + PPRE2; 12: TNT + RXR + PPARc + PPRE2.
doi:10.1371/journal.pone.0014629.g004
Figure 5. Effect of FBS, FBSLess (FBS with low fatty acids levels)
and hexanal on CYP1A1 mRNA levels. C: control cells; FBS: cells
treated with 20% FBS; FBSLess: cells treated with 20% FBSLess; hexanal:
cells treated with 25 mM hexanal (5A). Effect of various hexanal
concentrations (5, 10, 25, 50, 100 and 200 mM) on CYP1A1 mRNA level
(5B).
doi:10.1371/journal.pone.0014629.g005
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that these two PPRE sequences might act through PPARa. This
hypothesis was supported by EMSA. As shown in Figure 4, we
compared the specificity of each CYP1A1 PPRE sequence toward
PPARa or PPARc. The results (Figure 4, lanes 11–12) indicate
that the PPRE2 core is specific for PPARa. PPARc was unable to
recognize the PPRE2 core (Figure 4, lane 12). By contrast, PPARc
recognized a PPRE core sequence (Figure 4, lane 4) as well as
PPRE1 (Figure 4 lane 8).
Characterization of the serum compound involved in
CP1A1 induction
Hydrophobic entities present in FBS (Figure 2) induce CYP1A1
through a PPARa pathway (Figure 3). To determine their nature
we analyzed two sets of serum harboring different CYP1A1
induction capabilities. The results, presented in Figure 5A,
demonstrate that the serum usually used in this study (FBS)
induced CYP1A1, unlike the second serum characterized by a
naturally low FA content (FBSLess). We analyzed the lipid
composition (Table 1) and FA profile (Figure 6) of each serum.
The results show that FBS had higher lipid content and contained
four times more free FA than FBSLess (Table 1). In addition, FBS
contained a higher proportion of saturated FA (54% vs. 42%), and
a lower proportion of PUFA (13% vs. 23%) than did FBSLess, but
the same proportions of mono-unsaturated FA (33% vs. 34%)
(Figure 6). These data suggest a link between the free FA level and
the inducibility of CYP1A1. In further experiments using cells
treated with various free FA (palmitic acid, stearic acid, linoleic
acid, linolenic acid, arachidonic acid and eicosapentaenoic acid)
we did not observe any CYP1A1 induction (data not shown). As
PUFA levels were lower in FBS than in FBSLess, and as PUFA are
very sensitive to peroxidation, we performed HS-SPME-GC-MS
analysis of the two batches of serum to look for oxidative
derivatives (Figure 7A and B). We found that in contrast to
FBSLess (Figure 7B), FBS was rich in hexanal (approx. 28 mM), a
substance arising specifically from the peroxidation of linoleic acid
(Figure 7A). Among the different entities found and presented in
Figure 7, the only major substance detected derived from FA
peroxidation was hexanal. We therefore treated CaCo-2 cells with
hexanal. The results, presented in Figure 5, show that hexanal
induced CYP1A1 to an extent similar to that obtained using FBS
(7.2- and 10-fold respectively). This finding confirmed the role of
hexanal in CYP1A1 induction by serum. We realized a set of
experiments to confirm the role of hexanal in CYP1A1 induction
via PPARa. We treated (Figure 5A) CaCo-2 cells with 25 mMo f
hexanal and we showed that CYP1A1 was induced. We also
studied the effect of different hexanal concentrations in CYP1A1
induction. The results presented in Figure 5B demonstrated that
the CYP1A1 inductibility was linked to the hexanal concentration
between 1 to 25 mM. Above 25 mM of hexanal, the CYP1A1
induction decrease strongly due to the toxicity of this aldehydic
compound.
Discussion
Although AhR was initially considered as mandatory for
CYP1A1 gene expression [24], our data demonstrate that serum
induces CYP1A1 expression and that this induction involved
PPARa. Fractionation experiments on FBS suggested that
hydrophobic entities were involved. These were probably not
proteins, since ammonium sulfate precipitation of proteins did not
affect CYP1A1 induction by FBS (data not shown). These findings
led us to hypothesize that serum induced CYP1A1 via a ligand
able to bind to a member of the steroid hormone nuclear receptor
family.
The CYP1A1 promoter harbors several regulatory elements
including two PPRE and one RARE. Our team had previously
shown that the predominant effect of retinoids (RAR ligands) on
CYP1A1 expression was an inhibition of AhR-mediated induction,
acting through interference between the SMRT corepressor and
Figure 6. Fatty acid profile of total lipid extract of FBS (black bars) and FBSless (white bars). The data are expressed as weight % of total
fatty acids and represent the mean 6 SEM of three different determinations. *indicates significant differences between the sera for a given fatty acid
(p,0.05).
doi:10.1371/journal.pone.0014629.g006
Table 1. Lipid composition of FBS and FBSLess (mM) sera.
Lipids FBS FBSLess
Triglycerides, mM 1.2660.02* 0.8660.03
Total cholesterol, mM 1.1160.03* 0.7260.01
Free fatty acids, mM 0.4760.02* 0.1260.01
Phospholipids, mM 0.7260.04* 0.2360.01
Total lipids, g/L 1.860.03* 1.0260.06
Measurements were made in triplicate. Data represent mean 6 SEM.
*indicates significant differences between the sera for a given lipid parameter
(Mann-Whitney U test, p,0.05).
doi:10.1371/journal.pone.0014629.t001
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context of the present study since FBS potentiates AhR-mediated
CYP1A1 induction [16].
CaCo-2 cells express a high level of PPARc, but TZD failed to
induce CYP1A1. By contrast, we demonstrated that PPARa
played a significant role in CYP1A1 up-regulation. The involve-
ment of PPRE sequences in the serum induction is shown in our
study (Figure 3). We note that the PPRE2 site located at position
–519/-531 is specific for the PPARa isotype and is not recognized
by PPARc (Figure 4). This is the first demonstration of a
differential specificity among PPREa. PPARc is able to bind to the
PPRE1 site located at position –931/-919 (Figure 4), but the
specific PPARc ligand TZD was unable to induce CYP1A1
(Figure 3A), as previously described for troglitazone [12].
Mutagenesis of each PPRE site or of the two sites suppressed the
FBS and WY induction but not the 3-MC-mediated CYP1A1
induction (Figure 3B). We observed a slight decrease of luciferase
activity after a 3-MC treatment in the two PPRE mutation groups,
but this decrease is not significant. Furthermore, we showed in
Figure 1B that the PPARa ligands are not able to activate the
XRE. We therefore suppose that the absence of PPARa binding
on the CYP1A1 promoter after mutation can induce a
conformational change of the promoter structure leading to a
decrease of the activity of AhR on XRE sequences.
Subjects exposed to AhR agonists and exhibiting high blood levels of
endogenous PPARa ligands would therefore be expected to present a
greater risk of developing intestinal or pulmonary cancers and/or other
diseases related to CYP1A1 overexpression. This is in agreement with
epidemiological data showing that a high-fat diet increases the risk of
colon cancer [25]. Dietaryexposure to food-derived heterocyclic amine
carcinogens and polycyclic aromatic hydrocarbons has been proposed
as a specific risk factor [26], [27], [28].
Figure 7. HS-SPME-GC-MS analyses of the volatiles in FBS (A) and FBSLess (B) sera. Analyses were conducted with a 1 mL aliquot of each
serum. The black arrow indicates the presence of hexanal. List of the different substances found in the sera in order of retention time: for A, acetone,
2-butanone, 2-propanol, ethanol + CH2CL2, hexanal, 1-butanol, 1-penten-3-ol, pentanol, 1-hexanol or isomer, cyclohexanol, acetic acid, 1-hexanol,
2-ethyl; for B, hydrocarb, hydrocarb C8 # 1, hydrocarb C8 # 2, hydrocarb C8 acetone, 2,4-dimethyl-1-heptene, 2-butanone, 2-propanol, ethanol,
unknown, styrene, cyclohexanone, cyclohexanol, m-di-tert-butylbenzene, acetic acid, 1-hexanol, 2-ethyl.
doi:10.1371/journal.pone.0014629.g007
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compounds is hexanal. This substance is one of the primary
oxidative metabolites belonging to the saturated aldehyde family
and is the one most abundantly formed during peroxidation of
linoleic acid [29], [30], [31]. LA availability in humans is high. It is
supplied in the Western diet, with a consumption in the range 8-12
g/d in adults [32], [33], [34], and is commonly present in the
human body in blood, in the range 18–27% of total plasma fatty
acids [34], [35], and in tissues. LA can undergo oxidative stress,
leading in part to the generation of hydroxy radicals in a variety of
pathological states. More specifically, hexanal has been proposed
as a volatile cancer biomarker found in blood for lung cancer [36]
and more recently for liver cancer [37]. However, nothing has yet
been reported on the impact of hexanal on intestinal cell function.
Here we describe a new impact of hexanal on a human intestinal
cell line. People with high circulating hexanal blood levels, leading
to a higher CYP1A1 expression, may thus be at higher risk of
developing a colorectal cancer, as was demonstrated for genetic
polymorphisms increasing CYP1A1 expression or activity [28].
In conclusion, we have characterized the mechanism involved
in CYP1A1 induction in the human colon by serum and we show
that hexanal may be at least partly responsible for this induction.
PPARa transcription factor and two PPRE sites within the
CYP1A1 promoter are involved, and one PPRE, the PPRE2 site,
appears to be specific for the human PPARa.
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